{"id":306,"date":"2026-08-30T05:02:45","date_gmt":"2026-08-30T05:02:45","guid":{"rendered":"https:\/\/dentaltransitions.com\/articles\/sell-dental-practice-to-dso\/"},"modified":"2026-08-30T05:02:45","modified_gmt":"2026-08-30T05:02:45","slug":"sell-dental-practice-to-dso","status":"publish","type":"post","link":"https:\/\/dentaltransitions.com\/articles\/sell-dental-practice-to-dso\/","title":{"rendered":"How to Sell Your Dental Practice to a DSO"},"content":{"rendered":"<h2 id=\"key-takeaways\">Key Takeaways<\/h2>\n<ul>\n<li>DSO transactions often combine cash at close, rollover equity, and multi-year employment agreements, so each piece needs separate, careful review.<\/li>\n<li>Premier practices ($1.5M+ revenue) can benefit from a comparative valuation that weighs private-buyer and DSO offers side by side.<\/li>\n<li>A structured, multi-buyer bid process can be one of the main ways to raise valuations and reduce the risk of re-trading during diligence.<\/li>\n<li>Buyer vetting can be one of the main safeguards when a meaningful share of deal value is paid in equity, especially around platform financial health, management, clinical autonomy, and private equity (PE) sponsor history.<\/li>\n<li>McLerran &amp; Associates guides dentists through the full DSO transition process with comparative valuations and competitive bid management, so owners can make informed, data-driven decisions about their exit path. <a href=\"https:\/\/dentaltransitions.com\/contact-us\/\" target=\"_blank\">Start with a free, confidential discovery call<\/a>.<\/li>\n<\/ul>\n<h2>What \u201cSelling to a DSO\u201d Actually Involves<\/h2>\n<p>A DSO affiliation is not a simple handoff. The selling dentist simultaneously becomes a seller, a partner, and an investor. Most DSO deals combine cash at closing, retained rollover equity in the DSO or its holding company, an employment agreement requiring continued practice, and sometimes an earnout tied to future performance targets, rather than consisting of all-cash consideration. Each component behaves differently over time, so a clear view of how they work together can be the starting point for a sound decision.<\/p>\n<h2>Understand Your Options: Private Buyer vs. DSO Path<\/h2>\n<p>Premier-practice owners, generally those generating $1 million or more in annual revenue, with the DSO path more common for practices of $1.5 million or more, can realistically pursue two distinct transition paths. The table below compares the most material dimensions of each path and highlights a core tradeoff: private-buyer deals tend to offer simplicity and immediate liquidity, while DSO deals often offer higher headline valuations in exchange for more complexity, continued employment, and illiquid equity. Every figure reflects ranges drawn from current market data and McLerran &amp; Associates\u2019 transaction experience.<\/p>\n<table>\n<thead>\n<tr>\n<th>Dimension<\/th>\n<th>Private Buyer (Doctor-to-Doctor)<\/th>\n<th>DSO \/ Private Equity Affiliation<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Valuation method<\/td>\n<td>Percentage of trailing collections or multiple of net cash flow<\/td>\n<td>Multiple of adjusted EBITDA<\/td>\n<\/tr>\n<tr>\n<td>Typical headline premium<\/td>\n<td>Baseline<\/td>\n<td>Often higher than private-buyer offers for practices with meaningful EBITDA<\/td>\n<\/tr>\n<tr>\n<td>Cash at close<\/td>\n<td>Typically 100% of purchase price at closing<\/td>\n<td>60\u201380% cash at close, remainder in equity and\/or earnout<\/td>\n<\/tr>\n<tr>\n<td>Post-sale work obligation<\/td>\n<td>~4\u20138 weeks (walk-away sale) or phased vest-out<\/td>\n<td>3\u20135 years of continued clinical employment<\/td>\n<\/tr>\n<tr>\n<td>Diligence timeline<\/td>\n<td>30\u201360 days, focused on financials and equipment<\/td>\n<td>3\u20136 months of active process due to corporate diligence<\/td>\n<\/tr>\n<tr>\n<td>Equity component<\/td>\n<td>None in most cases<\/td>\n<td>15\u201340% rollover equity, illiquid until a future platform sale or recapitalization<\/td>\n<\/tr>\n<tr>\n<td>Complexity<\/td>\n<td>Lower, asset purchase agreement and standard financing<\/td>\n<td>Higher, LOI, quality-of-earnings review, employment agreement, equity documents<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Neither path fits every owner. Many practices in the $1.5\u20133 million revenue range can qualify for both, which is why a dual-market analysis that quantifies value in each market can be more reliable than guessing based on anecdotes.<\/p>\n<p><a href=\"https:\/\/dentaltransitions.com\/contact-us\/\" target=\"_blank\">Request a confidential review with McLerran &amp; Associates<\/a> to see how your practice might perform in both the private-buyer and DSO markets.<\/p>\n<figure style=\"text-align: center;\"><img src=\"https:\/\/cdn.aigrowthmarketer.co\/1782231776232-426cf610db07.jpeg\" alt=\"A chat at McLerran &amp; Associates: the dental-specific sell-side advisor and advocate for practice owners guides on how, when, and to whom to sell your practice.\" style=\"max-height: 500px;\" loading=\"lazy\" decoding=\"async\"><figcaption><em>A chat at McLerran &amp; Associates: the dental-specific sell-side advisor and advocate for practice owners guides on how, when, and to whom to sell your practice.<\/em><\/figcaption><\/figure>\n<h2>Create Competition Among DSO Buyers<\/h2>\n<p>A practice owner usually sells once in a career, while a DSO negotiates acquisitions every week. That information gap, with an individual dentist facing an institutional deal team, can be one of the main sources of lost value in dental transitions. A competitive process can help rebalance that dynamic.<\/p>\n<p>McLerran &amp; Associates runs a structured, auction-style bid process over roughly 45\u201360 days that often generates around 10 offers from a vetted pool of well-qualified DSO and private equity buyers. Poorly run or undercapitalized DSOs are screened out before the process begins, so owners interact only with credible counterparties. Clients in this type of process can often see meaningfully higher valuations than owners who negotiate alone or with a single buyer.<\/p>\n<p>Market data also supports the value of competition. <a href=\"https:\/\/privatepracticeresearch.org\/reports\/how-dental-practices-are-valued-2026\" target=\"_blank\" rel=\"noindex nofollow\">Practices taken to market through a structured multi-buyer process can achieve final sale values averaging meaningfully above initial unsolicited DSO offers<\/a>. And <a href=\"https:\/\/beckersdental.com\/dso-dpms\/69-of-dsos-plan-to-boost-acquisitions-in-2026-report\" target=\"_blank\" rel=\"noindex nofollow\">69% of DSOs surveyed in a Q2 2026 market report indicated their private equity sponsors expect a moderate or high increase in acquisition activity in 2026<\/a>, so buyer demand for premier practices remains strong, along with close scrutiny of financials and clinical continuity.<\/p>\n<p>The competitive process can also reduce the risk of re-trading, which is the common practice of a buyer lowering an offer during diligence after the seller has already stopped talking to other buyers. When other vetted bidders remain in the wings, that leverage weakens.<\/p>\n<p>Ready to see what a competitive bid process could mean for your practice? <a href=\"https:\/\/dentaltransitions.com\/contact-us\/\" target=\"_blank\">Begin with a free, confidential discovery call with McLerran &amp; Associates<\/a>.<\/p>\n<h2>Find the Right Fit: Buyer-Vetting Criteria<\/h2>\n<p>The highest bidder does not always provide the best long-term fit. Given the significant equity component discussed earlier, the selling dentist effectively becomes an investor in the acquiring platform. Vetting that platform with an investor\u2019s mindset can help protect both financial outcomes and quality of life.<\/p>\n<table>\n<thead>\n<tr>\n<th>Vetting Dimension<\/th>\n<th>What to Evaluate<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>Financial health<\/td>\n<td>Platform profitability, revenue growth at existing offices, debt levels<\/td>\n<td>Several large DSOs have undergone major debt restructurings, and equity in a distressed platform can be worth little<\/td>\n<\/tr>\n<tr>\n<td>Private equity backing<\/td>\n<td>Sponsor track record, fund vintage, remaining hold period<\/td>\n<td>A PE fund nearing the end of its hold period may prioritize a quick exit over long-term platform investment<\/td>\n<\/tr>\n<tr>\n<td>Management team<\/td>\n<td>Dental-specific operating experience, seller references<\/td>\n<td>Post-close quality of life can depend heavily on who is running the platform<\/td>\n<\/tr>\n<tr>\n<td>Clinical autonomy<\/td>\n<td>Treatment protocols, production expectations, staffing control<\/td>\n<td>Contractual promises about autonomy should align with the experience of existing affiliated dentists<\/td>\n<\/tr>\n<tr>\n<td>Support infrastructure<\/td>\n<td>HR, payroll, compliance, IT, marketing, procurement<\/td>\n<td>These are the basic services a DSO should deliver, and gaps can create extra work for the selling dentist after closing<\/td>\n<\/tr>\n<tr>\n<td>Non-compete scope<\/td>\n<td>Geographic radius and duration<\/td>\n<td>Non-competes in dental practice sales should specify a reasonable geographic scope and duration, and overly broad provisions often need careful negotiation<\/td>\n<\/tr>\n<tr>\n<td>Post-close employment terms<\/td>\n<td>Compensation structure, minimum term, earnout conditions<\/td>\n<td>Many DSOs require a multi-year post-close employment term to close a transaction, and compensation typically shifts to an associate production split<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>McLerran &amp; Associates vets buyers before they reach the table. The firm steers clients toward well-backed, well-run partners with a record of satisfied sellers and away from platforms that have created poor post-close environments or carry excessive leverage.<\/p>\n<p>If you want help assessing specific DSO suitors, <a href=\"https:\/\/dentaltransitions.com\/contact-us\/\" target=\"_blank\">schedule a confidential conversation with McLerran &amp; Associates<\/a> to align buyer selection with your clinical and financial goals.<\/p>\n<h2>Maximize Your Outcome: Valuation Mechanics and Deal Structure<\/h2>\n<h3>How EBITDA Valuation and Add-Backs Work<\/h3>\n<p>In a DSO transaction, the practice is usually priced as a multiple of adjusted EBITDA, not collections. EBITDA stands for earnings before interest, taxes, depreciation, and amortization, and adjusted EBITDA starts with the practice\u2019s reported operating profit, then adds back discretionary, personal, and one-time expenses that a new owner would not expect to pay. Common add-backs include owner compensation above a market-rate associate salary, personal vehicle expenses, excess retirement contributions, family members on payroll without proportional work, and one-time costs. Buyers reconcile tax returns to profit-and-loss statements and require complete supporting documentation for every add-back, and incomplete support can create purchase-price adjustments or indemnification escrows.<\/p>\n<p>McLerran &amp; Associates builds a CPA-led, diligence-grade EBITDA analysis before the practice goes to market, so the number has support when buyers review it and the deal is less likely to be re-traded later. <a href=\"https:\/\/privatepracticeresearch.org\/reports\/how-dental-practices-are-valued-2026\" target=\"_blank\" rel=\"noindex nofollow\">Current market data indicate that EBITDA multiples for U.S. dental practices sold to DSOs or private equity buyers range broadly from approximately 5x to 11x or higher, stratified by practice EBITDA size and buyer type<\/a>. Specialty practices can sometimes command a premium over general dentistry at comparable size. The specific multiple a practice achieves can depend on its fundamentals, not a fixed table.<\/p>\n<figure style=\"text-align: center;\"><img src=\"https:\/\/cdn.aigrowthmarketer.co\/1782231605342-03c5ed4725a3.jpeg\" alt=\"At McLerran &amp; Associates, every engagement is built on an ironclad, CPA-led EBITDA analysis and practice valuation.\" style=\"max-height: 500px;\" loading=\"lazy\" decoding=\"async\"><figcaption><em>At McLerran &amp; Associates, every engagement is built on an ironclad, CPA-led EBITDA analysis and practice valuation.<\/em><\/figcaption><\/figure>\n<p>With that foundation in place, the following checklist walks through a practical preparation and negotiation sequence, from building your EBITDA analysis to defending it through diligence.<\/p>\n<h3>7-Step Checklist for a Strong DSO Offer<\/h3>\n<ol>\n<li><strong>Confirm the adjusted EBITDA figure<\/strong> with a CPA-led analysis before any buyer conversation begins.<\/li>\n<li><strong>Build a virtual data room<\/strong> with 3\u20135 years of financials, production reports by provider, payer mix, lease documents, staff records, and compliance documentation.<\/li>\n<li><strong>Run a competitive bid process<\/strong> among multiple vetted buyers, not a single unsolicited offer.<\/li>\n<li><strong>Model all three consideration components<\/strong> separately: cash at close, rollover equity, and earnout.<\/li>\n<li><strong>Underwrite the DSO\u2019s equity<\/strong> as an investment by reviewing platform profitability, debt levels, management team, and PE sponsor track record.<\/li>\n<li><strong>Negotiate LOI terms<\/strong> before exclusivity, including earnout structure, non-compete scope, employment compensation, and equity level, whether joint-venture or holding-company.<\/li>\n<li><strong>Defend EBITDA through diligence<\/strong> with a quality-of-earnings advocate who can respond if the buyer attempts to re-trade the agreed value.<\/li>\n<\/ol>\n<p>Once you have secured a strong offer, the next step is understanding how that offer may actually pay out over time, because the headline number tells only part of the story.<\/p>\n<h3>Cash vs. Equity vs. Earnout: Multi-Horizon Modeling<\/h3>\n<p>The table below illustrates how the three components of a DSO deal can behave across time horizons for a hypothetical premier practice. The comparison shows that cash is immediate but finite, earnouts are usually taxed as ordinary income and typically conclude within several years, and equity remains illiquid for 5\u201310 years but can multiply in value if the platform performs well. These are illustrative ranges based on McLerran &amp; Associates\u2019 transaction experience and current market structures, not guarantees. Consult your CPA and legal advisors for tax and legal guidance specific to your situation.<\/p>\n<table>\n<thead>\n<tr>\n<th>Horizon<\/th>\n<th>Cash at Close<\/th>\n<th>Rollover Equity (Illustrative)<\/th>\n<th>Earnout<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>At close<\/td>\n<td>Received immediately, typically 60\u201380% of total deal value<\/td>\n<td>Illiquid, no cash received yet<\/td>\n<td>Not yet earned, performance period begins<\/td>\n<\/tr>\n<tr>\n<td>3 years<\/td>\n<td>Often fully deployed or invested<\/td>\n<td>Still illiquid in many structures, value depends on platform performance<\/td>\n<td>Contingent payments over a 3\u20135 year period, taxed as ordinary income if tied to employment<\/td>\n<\/tr>\n<tr>\n<td>5\u20137 years<\/td>\n<td>N\/A<\/td>\n<td>Potential liquidity event, such as a secondary PE buyout or recapitalization, with gains taxed at long-term capital gains rates upon a liquidity event<\/td>\n<td>Earnout period typically concluded<\/td>\n<\/tr>\n<tr>\n<td>10 years<\/td>\n<td>N\/A<\/td>\n<td>Second or third recapitalization possible, and holding-company equity can multiply several times over in a well-run platform or be worth little in a distressed one<\/td>\n<td>N\/A<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Equity can sit at the joint-venture level, with distributions and a higher floor but lower ceiling, or at the holding-company level, which carries no distributions but higher potential upside. PE-backed DSOs commonly issue common equity or common-equivalent units to selling dentists, which sit behind the private equity sponsor\u2019s preferred stock or senior units that carry a liquidation preference, so common equity can be worth significantly less than expected if the platform sells at a modest discount to its valuation.<\/p>\n<p>After you understand how the economics may play out over time, the next focus becomes locking those economics into the letter of intent.<\/p>\n<h3>LOI Terms to Negotiate<\/h3>\n<p>The letter of intent (LOI) is the preliminary agreement that sets the deal\u2019s key terms before formal contracts are drafted, and most of the economic outcome is shaped here. Several related terms usually deserve close attention because they work together to define both price and risk:<\/p>\n<ul>\n<li>Total enterprise value and how it is split among cash, equity, and earnout, which defines your mix of immediate and future proceeds.<\/li>\n<li>Earnout structure, including pro-rata provisions so a near-miss on a target still pays most of the earnout, along with the start date and measurement period.<\/li>\n<li>Equity level, whether joint-venture or holding-company, plus protections such as anti-dilution and tag-along rights that affect future liquidity.<\/li>\n<li>Non-compete geographic radius and duration, which shape your future practice options.<\/li>\n<li>Post-close employment compensation and minimum term, which determine your income and schedule after closing.<\/li>\n<li>Exclusivity period length and conditions for termination, which influence your ability to re-engage other bidders if the deal stalls.<\/li>\n<\/ul>\n<p>Once LOI terms align with your goals, the final step is confirming that your day-to-day life after closing will match what you expect.<\/p>\n<h3>Post-Close Quality-of-Life Checklist<\/h3>\n<p>Before signing, many dentists find it helpful to confirm several quality-of-life items with the buyer in writing, since these details shape daily practice after the transaction:<\/p>\n<ul>\n<li>Clinical autonomy, including treatment protocols, referral patterns, and scheduling control.<\/li>\n<li>Staff retention commitments and compensation continuity, so your team understands what to expect.<\/li>\n<li>Infrastructure support across HR, payroll, compliance, IT, and marketing, which affects how much administrative work remains on your plate.<\/li>\n<li>Patient communication plan and transition timeline, to protect goodwill and patient trust.<\/li>\n<li>Escalation path if post-close commitments are not honored, so issues have a clear route to resolution.<\/li>\n<\/ul>\n<p>If you want to see how different structures could affect your real, after-tax proceeds over time, <a href=\"https:\/\/dentaltransitions.com\/contact-us\/\" target=\"_blank\">connect with McLerran &amp; Associates for a free, confidential modeling session<\/a>.<\/p>\n<h2>Frequently Asked Questions<\/h2>\n<h3>What percentage of a DSO deal is typically paid in cash at closing?<\/h3>\n<p>Most DSO transactions are structured so that cash at closing represents roughly 60\u201380% of the total deal value, with the remainder allocated to rollover equity and, in many cases, an earnout tied to post-close performance targets. The exact cash-at-close percentage can depend on the buyer, the practice\u2019s size and risk profile, and the negotiating leverage created by a competitive bid process. Owners who enter negotiations with a single DSO, without competitive tension, tend to receive less favorable cash-at-close terms than those who run a structured multi-buyer process. A high cash-at-close percentage, often above 70\u201375%, can be achievable in certain markets and practice profiles but is not universal. McLerran &amp; Associates can advise on what may be realistic for a specific practice based on current buyer behavior in that region.<\/p>\n<h3>How should I compare rollover equity across different DSO offers?<\/h3>\n<p>Rollover equity, which is the portion of deal proceeds retained as an ownership stake in the DSO\u2019s parent platform, cannot be compared on face value alone. The equity remains illiquid until a future liquidity event such as a secondary private equity buyout or platform recapitalization, which often occurs 5\u201310 years after closing. To compare offers in a meaningful way, evaluate the platform\u2019s current profitability, revenue growth at existing affiliated offices, total debt load relative to earnings, the private equity sponsor\u2019s track record, and the structure of the equity itself. That structure includes whether it is issued at the joint-venture level or the holding-company level, and whether it sits behind a preferred equity layer that carries a liquidation preference. McLerran &amp; Associates produces multi-year financial forecasting that models each finalist\u2019s equity under conservative recapitalization assumptions, so owners can compare risk-adjusted outcomes rather than just headline numbers.<\/p>\n<h3>What does a non-compete clause typically look like in a DSO deal, and is it negotiable?<\/h3>\n<p>Non-compete provisions in DSO dental practice transactions are typically negotiated with a reasonable geographic scope and a set duration following the end of the post-close employment period. Overly broad non-competes, such as those covering an entire state or metropolitan area, can be a red flag and often should be negotiated alongside price and equity terms, not treated as boilerplate. The scope and enforceability of non-competes also vary by state, which is why dental-specific legal counsel can be essential. McLerran &amp; Associates negotiates non-compete terms as part of the LOI process and can identify buyers whose standard agreements are more or less favorable on this dimension before the owner enters exclusivity.<\/p>\n<h3>How do I know if a DSO is financially stable enough to trust with my equity?<\/h3>\n<p>Financial stability can be one of the most important, and most overlooked, dimensions of DSO vetting. Several large DSO platforms have undergone significant debt restructurings in recent years, with lenders taking control after debt loads became unsustainable. Before accepting equity in any platform, an owner can review the DSO\u2019s audited financial statements, understand its total debt relative to earnings, assess whether the private equity sponsor\u2019s fund is early or late in its hold period, and speak with dentists who have already affiliated with that platform. McLerran &amp; Associates vets buyers as part of its standard process, blacklisting DSOs known for poor post-close environments or financial instability, and helps clients underwrite the equity component of any offer with the same care they would apply to any significant investment.<\/p>\n<h2>Conclusion: Control the Narrative and Protect Your Legacy<\/h2>\n<p>Selling your dental practice to a DSO is a once-in-a-lifetime decision that tends to reward preparation, competition, and disciplined deal structuring, and it can penalize information gaps. The four-part journey, Understand Your Options, Create Competition, Find the Right Fit, and Maximize Your Outcome, reflects a practical sequence that often shapes whether an owner captures the full value of what they built or leaves money and protection on the table.<\/p>\n<p>McLerran &amp; Associates has guided dentists through approximately 2,000 successful practice sales totaling roughly $2 billion in closed transaction volume, with more than 10,000 practices evaluated over approximately 35 years. The firm works both transition paths, private-buyer and DSO, in roughly equal measure, which gives clients a genuine comparative view that single-lane brokers may not provide. The result is a transaction rate of approximately 85\u201390%, compared to an industry norm closer to 35\u201340%. McLerran focuses on completing transactions, not just listing practices.<\/p>\n<figure style=\"text-align: center;\"><img src=\"https:\/\/cdn.aigrowthmarketer.co\/1782231581955-2aa75d9d4697.jpeg\" alt=\"McLerran &amp; Associates team: McLerran is the nation's largest dental-specific sell-side M&amp;A advisory and brokerage firms\" style=\"max-height: 500px;\" loading=\"lazy\" decoding=\"async\"><figcaption><em>McLerran &amp; Associates team: McLerran is the nation&#8217;s largest dental-specific sell-side M&amp;A advisory and brokerage firms<\/em><\/figcaption><\/figure>\n<p>Demand for premier, Class A practices remains strong, and valuations currently sit near historically high levels. The window appears open, but the process can be unforgiving without the right advocate in the room.<\/p>\n<p><strong>Ready to understand what your practice is really worth and how a competitive process could shape your outcome?<\/strong> <a href=\"https:\/\/dentaltransitions.com\/contact-us\/\" target=\"_blank\">Schedule a free, confidential discovery call with McLerran &amp; Associates today.<\/a> Call <strong>(512) 900-7989<\/strong>, email <strong>info@dentaltransitions.com<\/strong>, or visit <strong>dentaltransitions.com\/contact-us<\/strong>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Selling to a DSO? McLerran &#038; Associates helps dentists maximize value, structure deals, and protect their legacy. Get expert guidance today.<\/p>\n","protected":false},"author":1,"featured_media":305,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-306","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/posts\/306","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/comments?post=306"}],"version-history":[{"count":0,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/posts\/306\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/media\/305"}],"wp:attachment":[{"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/media?parent=306"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/categories?post=306"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dentaltransitions.com\/articles\/wp-json\/wp\/v2\/tags?post=306"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}